Equities

Hisamitsu Pharmaceutical Co Inc

Hisamitsu Pharmaceutical Co Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (JPY)3,948.00
  • Today's Change38.00 / 0.97%
  • Shares traded74.40k
  • 1 Year change-25.96%
  • Beta0.8575
Data delayed at least 20 minutes, as of Sep 19 2024 07:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 14-Sep-23
  • 20-Jun-24
  • 18-Jul-24
  • 15-Aug-24
  • 12-Sep-24
Select bar for recommendation details.
Recommendations12-Sep-24
Buy0
Outperform0
Hold1
Sell0
Strong Sell0

Share price forecast in JPY

The one analyst offering a 12 month price target expects Hisamitsu Pharmaceutical Co Inc share price to rise to 4,350.00 in the next year from the last price of 3,948.00.
High10.2%4,350.00
Med10.2%4,350.00
Low10.2%4,350.00

Dividends in JPY

In 2024, Hisamitsu Pharmaceutical Co Inc reported a dividend of 85.00 JPY, which represents a 1.19% increase over last year. The analyst covering the company expects dividends of 90.00 JPY for the upcoming fiscal year, an increase of 5.88%.
Div growth (TTM)1.19%
More ▼

Earnings history & estimates in JPY

On Jul 11, 2024, Hisamitsu Pharmaceutical Co Inc reported 1st quarter 2025 earnings of 63.89 per share. This result exceeded the 53.20 expectation of the one analyst covering the company and exceeded last year's 1st quarter results by 22.67%.
Average growth rate+26.24%
Hisamitsu Pharmaceutical Co Inc reported annual 2024 earnings of 181.62 per share on Apr 11, 2024.
Average growth rate+0.49%
More ▼

Revenue history & estimates in JPY

Hisamitsu Pharmaceutical Co., Inc. had 1st quarter 2025 revenues of 35.81m. This bettered the 35.80m estimate of the one analyst covering the company. This was 11.57% above the prior year's 1st quarter results.
Average growth rate+3.00%
Hisamitsu Pharmaceutical Co., Inc. had revenues for the full year 2024 of 141.71m. This was 10.42% above the prior year's results.
Average growth rate+0.84%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.